Co-stimulatory blockade as therapy for rheumatoid arthritis

Curr Rheumatol Rep. 2005 Oct;7(5):400-6. doi: 10.1007/s11926-005-0029-4.


There is substantial evidence that rheumatoid arthritis is an autoimmune disease in which T cells are aberrantly activated. Existing therapies, including anti-tumor necrosis factor therapies, are successful for many patients, but the goal of lasting remission still frequently proves elusive. One novel therapeutic strategy is the blockade of T-cell co-stimulation to modulate T-cell activation. The first co-stimulation blocker to reach clinical trials is abatacept (CTLA4Ig). Initial abatacept trials have shown promise and further phase III trials are underway.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Humans
  • Immunoconjugates / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Lymphocyte Activation / drug effects*
  • Lymphocyte Activation / immunology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Treatment Outcome


  • Immunoconjugates
  • Immunologic Factors